• Release your full potential

    Be free to be active. Converting knowledge in skin biology into treatment satisfaction

ABOUT US

MC2 Therapeutics is a commercial stage pharmaceutical company committed to research in skin biology and development of novel treatment paradigms for people with autoimmune and chronic inflammatory skin conditions. Read more about MC2 Therapeutics.

Platform

Our PAD Technology™ formulation and drug delivery system offer several unique advantages in the development of potent innovative new topical therapies for auto-immune and inflammatory conditions, including stability, tolerability, delivery to target tissue and convenience of use in daily routines. Read more about our platform.

Pipeline

MC2 therapeutics is converting skin biology into novel treatment paradigms for autoimmune and inflammatory skin conditions. Our innovative approach to address complex challenges more effectively is anchored in deep understanding of the skin biology combined with learnings from the pathophysiology across disease segments. Fuelled by an entrepreneurial and creative mindset we aim to bring forward breakthrough discoveries and innovative technologies. Our drug candidates are powered by our proprietary formulation and drug delivery system PAD Technology™. Read more about our pipeline.

LATEST NEWS

mc2_news-image-icon-05

MC2 Therapeutics announces initiation of a Phase 2 clinical trial in CKD-aP

  • Trial based on the recent breakthrough discovery of a novel treatment paradigm for urea associated ...

    READ FULL ARTICLE

mc2_news-image-icon-04

MC2 Therapeutics announces breakthrough discovery with the potential to help millions of people suffering from urea associated skin diseases

  • Breakthrough discovery of a novel biological paradigm for treatment of several urea associated skin diseases
  • MC2 ...

    READ FULL ARTICLE

 

mc2_news-image-icon-07

Professor Lars Iversen joins MC2 Therapeutics as new Chief Medical Officer

Copenhagen, June 9th 2022 – MC2 Therapeutics A/S, a commercial stage pharmaceutical company, has named ...

READ FULL ARTICLE

mc2_news-image-icon-04

MC2 Therapeutics’ clinical research to be presented in four poster presentations at the European Academy of Dermatology and Venereology conference - EADV 2021

  • Poster # P1447: A pooled analysis of randomized, controlled, phase 3 trials investigating the efficacy ...

    READ FULL ARTICLE